ストックスクリーナーアプリを入手
6.75
1.49%
-0.12
前日終値:
$6.87
開ける：
$6.82
24時間の取引高:
1.23M
Relative Volume:
0.24
時価総額：
$1.76B
収益：
$6.28B
当期純損益:
$700.00M
株価収益率:
2.5072
EPS:
2.6922
ネットキャッシュフロー:
$537.00M
1週間 パフォーマンス:
-6.39%
1か月 パフォーマンス:
-16.45%
6か月 パフォーマンス:
-34.80%
1年 パフォーマンス:
-53.16%
1日の値動き範囲:
$6.72
$6.98
1週間の範囲:
$6.72
$7.34
52週間の値動き範囲:
$6.18
$16.08
Organon Co Stock (OGN) Company Profile
Compare OGN vs LLY, JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.755 | 1.79B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
973.27 | 896.18B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.01 | 591.15B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.14 | 417.62B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.35 | 315.13B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
196.28 | 312.52B | 58.80B | 10.24B | 8.98B | 3.2788 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-10-27 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat
Organon price target raised to $8 from $7.50 at Barclays - TipRanks
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India
Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²
Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com
Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI
Organon enters into agreement to license Miudella® - marketscreener.com
First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan
Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st
Organon rises after update on independent review - MSN
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon Shares Rally as Investigation Clears Company of Wrongdoing - AD HOC NEWS
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Up 6.6%What's Next? - MarketBeat
Sector Update: Health Care - marketscreener.com
Organon Says Audit Review of Biosimilar Purchases Finds No Issues - marketscreener.com
Organon & Co. audit committee completes review of biosimilar purchase timing By Investing.com - Investing.com South Africa
Organon & Co. audit committee completes review of biosimilar purchase timing - Investing.com Nigeria
Organon rises after update on independent review (OGN:NYSE) - Seeking Alpha
Organon Audit Review Finds No Issues, 10-K On Track - TipRanks
Organon shares jump 6% after audit finds no misconduct By Investing.com - Investing.com India
Organon shares jump 6% after audit finds no misconduct - Investing.com
Organon (OGN) audit review finds no misconduct, plans timely 2025 10-K - Stock Titan
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
0.32%
大文字化:
|
ボリューム (24 時間):